| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1828 | 2020 |
| Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium P Grivas, AR Khaki, TM Wise-Draper, B French, C Hennessy, CY Hsu, ... Annals of oncology 32 (6), 787-800, 2021 | 287 | 2021 |
| Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ... JAMA oncology 7 (8), 1167-1175, 2021 | 169 | 2021 |
| EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience M Atiq, MS Bhutani, M Bektas, JE Lee, Y Gong, EP Tamm, CP Shah, ... Digestive diseases and sciences 57, 791-800, 2012 | 107 | 2012 |
| Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis C Shah, R Bishnoi, A Jain, H Bejjanki, S Xiong, Y Wang, F Zou, JS Moreb Leukemia & lymphoma 59 (11), 2557-2569, 2018 | 68 | 2018 |
| Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint … R Bishnoi, YR Hong, C Shah, A Ali, WP Skelton IV, J Huo, NH Dang, ... Cancer medicine 8 (8), 3918-3927, 2019 | 48 | 2019 |
| A multi‑center retrospective analysis of the effect of DPP4 inhibitors on progression‑free survival in advanced airway and colorectal cancers A Ali, A Fuentes, WP Skelton Iv, Y Wang, S McGorray, C Shah, R Bishnoi, ... Molecular and clinical oncology 10 (1), 118-124, 2019 | 37 | 2019 |
| Survival differences among patients with hepatocellular carcinoma based on the stage of disease and therapy received: pre and post sorafenib era C Shah, LK Mramba, R Bishnoi, H Bejjanki, HS Chhatrala, SR Chandana Journal of Gastrointestinal Oncology 8 (5), 789, 2017 | 34 | 2017 |
| Cardiotoxicity due to targeted anticancer agents: a growing challenge CP Shah, JS Moreb Therapeutic Advances in Cardiovascular Disease 13, 1753944719843435, 2019 | 33 | 2019 |
| Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis R Bishnoi, Z Xie, C Shah, J Bian, HS Murthy, JR Wingard, N Farhadfar Cancer medicine 10 (1), 70-78, 2021 | 32 | 2021 |
| The role of a best practice alert in the electronic medical record in reducing repetitive lab tests H Bejjanki, LK Mramba, SG Beal, N Radhakrishnan, R Bishnoi, C Shah, ... ClinicoEconomics and Outcomes Research, 611-618, 2018 | 32 | 2018 |
| Predicting in-hospital mortality of patients with febrile neutropenia using machine learning models X Du, J Min, CP Shah, R Bishnoi, WR Hogan, DJ Lemas International journal of medical informatics 139, 104140, 2020 | 31 | 2020 |
| Impact of DPP4 inhibitors in survival of patients with prostate, pancreas, and breast cancer C Shah, YR Hong, R Bishnoi, A Ali, WP Skelton IV, LH Dang, J Huo, ... Frontiers in Oncology 10, 405, 2020 | 28 | 2020 |
| Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials C Shah, R Bishnoi, Y Wang, F Zou, H Bejjanki, S Master, JS Moreb Oncotarget 9 (34), 23704, 2018 | 26 | 2018 |
| Survival trends of metastatic small intestinal neuroendocrine tumor: a population-based analysis of SEER database CP Shah, LK Mramba, R Bishnoi, A Unnikrishnan, JM Duff, SR Chandana Journal of gastrointestinal oncology 10 (5), 869, 2019 | 24 | 2019 |
| Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center N Waheed, MG Fradley, DL DeRemer, A Mahmoud, CP Shah, ... Cardio-oncology 7, 1-7, 2021 | 22 | 2021 |
| A systematic framework to rapidly obtain data on patients with cancer and COVID-19: CCC19 governance, protocol, and quality assurance M Abidi, DM Aboulafia, MK Accordino, JD Acoba, MS Ahluwalia, ... Cancer cell 38 (6), 761-766, 2020 | 18 | 2020 |
| Desmoid tumor SR Master, A Mangla, Y Puckett, C Shah | 17 | 2017 |
| Unanticipated cardiotoxicity associated with targeted anticancer therapy in patients with hematologic malignancies patients: natural history and risk factors C Shah, Y Gong, A Szady, Q Sun, CJ Pepine, T Langaee, AR Lucas, ... Cardiovascular toxicology 18, 184-191, 2018 | 12 | 2018 |
| Lactate dehydrogenase B and pyruvate oxidation pathway associated with carfilzomib-related cardiotoxicity in multiple myeloma patients: result of a multi-omics integrative analysis M Tantawy, LM Chekka, Y Huang, TJ Garrett, S Singh, CP Shah, ... Frontiers in Cardiovascular Medicine 8, 645122, 2021 | 11 | 2021 |
Rohit BishnoiHematology-OncologyVerified email at medicine.ufl.edu
